Michael L Ganz
Tanzania
Research Article
Real-World Clinical Effectiveness of Liraglutide in Individuals 65 Years and Older with Type 2 Diabetes in the United States
Author(s): Abhishek Chitnis, Michael L Ganz, Mette Hammer and Jakob LangerAbhishek Chitnis, Michael L Ganz, Mette Hammer and Jakob Langer
Objective: Clinical trials have shown that liraglutide effectively lowers A1C levels and helps manage weight in Type 2 diabetes (T2D). Currently, no studies have solely evaluated the real-world clinical effectiveness of liraglutide in a T2D population of individuals 65 years and older. We examined the clinical effectiveness of liraglutide in individuals aged 65 years and older with T2D 6 and 12 months after starting therapy.
Methods: In this retrospective cohort study we used the General Electric Centricity electronic medical records database. We included individuals with T2D aged 65 years and older who initiated liraglutide at any time from January 1, 2010 to January 31, 2013. Individuals using either insulin or a glucagon-like peptide-1 analogue during 12 months before initiating liraglutide were excluded. Changes in A1C, weight, the proporti.. View More»
